BioNTech's Ugur Sahin and Özlem Türeci after receiving the Federal Cross of Merit, March 19, 2021 (Bernd von Jutrczenka/picture-alliance/dpa/AP Images)

BioN­Tech makes a splash with $10B+ pro­jec­tion for 2021 Covid-19 vac­cine sales

BioN­Tech, Pfiz­er’s rel­a­tive­ly qui­et Ger­man biotech part­ner for its Covid-19 vac­cine, made noise on Tues­day with its earn­ings re­port, pro­ject­ing about €10 bil­lion ($11.5 bil­lion) in vac­cine rev­enue based on the cur­rent­ly signed sup­ply con­tracts for about 1.4 bil­lion dos­es.

The €10 bil­lion pro­jec­tion for the grow­ing com­pa­ny, found­ed by the hus­band and wife team of Ugur Sahin and Özlem Türe­ci, comes al­most ex­act­ly a year af­ter the com­pa­ny first an­nounced its plans to join up with Pfiz­er and bring its mR­NA-based vac­cine to fruition. That pro­jec­tion al­so dwarfs Pfiz­er’s orig­i­nal agree­ment to pay BioN­Tech $185 mil­lion up­front for the vac­cine col­lab­o­ra­tion, even with the po­ten­tial fu­ture mile­stone pay­ments of up to $563 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.